<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Overview of the classification and management of cancers of unknown primary site</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Overview of the classification and management of cancers of unknown primary site</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Overview of the classification and management of cancers of unknown primary site</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John D Hainsworth, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">F Anthony Greco, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">George P Canellos, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sonali M Shah, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 15, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Cancer of unknown primary site (CUP) is a relatively common clinical entity, accounting for approximately 2 percent of all invasive cancers [<a href="#rid1">1</a>]. Within this category, tumors from many primary sites with varying biology are represented. This heterogeneity has made the design and interpretation of clinical studies difficult.</p><p>A general overview of the classification and management of CUP is presented here. Further specific details on the evaluation and management of specific subgroups of CUP are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4877.html" rel="external">"Adenocarcinoma of unknown primary site"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4880.html" rel="external">"Squamous cell carcinoma of unknown primary site"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4876.html" rel="external">"Neuroendocrine neoplasms of unknown primary site"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4875.html" rel="external">"Poorly differentiated cancer from an unknown primary site"</a>.)</p><p></p><p class="headingAnchor" id="H1318541839"><span class="h1">INITIAL DIAGNOSTIC EVALUATION</span><span class="headingEndMark"> — </span>Patients with CUPs typically present with symptoms referable to metastases. The initial diagnosis of advanced cancer is confirmed by biopsy of a metastatic lesion. The diagnosis of CUP is made only after specific diagnostic tests are performed and do not identify an anatomic primary site. (See <a class="local">'Subsequent evaluation of CUP'</a> below.)</p><p>The tests which are successful in identifying a primary site in most patients with advanced cancer include:</p><p class="bulletIndent1"><span class="glyph">●</span>History, physical examination (including pelvic exam in females).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Complete blood counts, serum chemistries, urinalysis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Serum prostate-specific antigen (PSA; in males).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Computed tomography (CT) scans of chest, abdomen, and pelvis (these procedures identify a primary site in 10 to 35 percent of patients [<a href="#rid2">2,3</a>]).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mammography (females).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Focused evaluation of specific signs/symptoms.</p><p></p><p class="headingAnchor" id="H2"><span class="h1">SUBSEQUENT EVALUATION OF CUP</span><span class="headingEndMark"> — </span>After the diagnosis of CUP is established, patients are classified into one of the following four categories based on the light microscopic examination of the initial biopsy. These classifications are used to guide further diagnostic evaluation. Patients in these histology-based groups also vary with respect to their clinical characteristics, treatment, and prognosis. </p><p class="bulletIndent1"><span class="glyph">●</span>Adenocarcinoma. (See <a class="local">'Adenocarcinoma'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Squamous cell carcinoma. (See <a class="local">'Squamous cell carcinoma'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Neuroendocrine carcinoma, which may be either well differentiated or poorly differentiated. (See <a class="local">'Neuroendocrine tumors'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Poorly differentiated tumors, most of which are recognized as carcinomas on histologic examination. Less frequently, the lineage (carcinoma, lymphoma, sarcoma, melanoma, germ cell tumor) is unclear after light microscopic examination. (See <a class="local">'Poorly differentiated cancers'</a> below.)</p><p></p><p>Most CUP patients receive further evaluation; this may include further clinical diagnostic procedures, but it almost always includes specialized pathologic testing to refine the initial histologic diagnosis. Still, in many patients with CUP, the anatomic primary site is often difficult to identify despite receiving optimal clinical and pathologic diagnostic evaluation [<a href="#rid4">4</a>].</p><p class="headingAnchor" id="H3"><span class="h2">Adenocarcinoma</span><span class="headingEndMark"> — </span>Adenocarcinomas of unknown primary site constitute approximately 70 percent of CUPs. The clinical presentation of patients with adenocarcinoma is determined by the sites of tumor involvement, which frequently include the liver, lungs, lymph nodes, and/or bones. (See  <a class="medical medical_review" href="/z/d/html/4877.html" rel="external">"Adenocarcinoma of unknown primary site"</a>.)</p><p>In autopsy series of patients with adenocarcinoma of unknown primary site, the most frequently identified malignancies were lung, pancreas, hepatobiliary tree, and kidney, together accounting for approximately two-thirds of cases [<a href="#rid5">5</a>]. However, tumors arising from a wide variety of other primary sites were also identified. Adenocarcinomas of the breast and prostate were infrequently identified in autopsy series, despite being the most common cancers in females and males, respectively [<a href="#rid6">6</a>].</p><p>In specific patient subgroups, several additional clinical studies are useful in identifying the anatomic primary site and thus in guiding therapy:</p><p class="bulletIndent1"><span class="glyph">●</span>In females with clinical presentations suggestive of metastatic breast cancer (eg, axillary adenopathy), breast magnetic resonance imaging (MRI) should be considered even if mammograms are normal. Immunochemical staining of the biopsy specimen may detect the expression of breast cancer-specific markers, such as estrogen and progesterone receptors, mammaglobin, and gross cystic duct fluid protein. (See  <a class="medical medical_review" href="/z/d/html/766.html" rel="external">"Axillary node metastases with occult primary breast cancer", section on 'Initial diagnostic workup'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Positron emission tomography (PET) is useful in specific clinical settings [<a href="#rid7">7-9</a>], but in most patients, it does not add substantially to the information obtained by computed tomography (CT) scans [<a href="#rid10">10</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Additional signs or symptoms, such as a positive test for occult blood in stool, should be evaluated with appropriate radiographic or endoscopic studies. Colonoscopy should also be performed in patients with intra-abdominal metastases (liver, peritoneum) and pathologic findings (histology and/or immunohistochemistry) typical of colon cancer, even in the absence of symptoms referable to the gastrointestinal tract. However, routine endoscopic evaluation of the upper and/or lower gastrointestinal tract has a low yield in other asymptomatic patients.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In males with clinical presentations suggestive of metastatic prostate cancer (eg, blastic bone metastases), tissue staining for prostate-specific antigen (PSA) is sometimes diagnostic even when serum PSA is not elevated.</p><p></p><p>The most important improvements to the evaluation of CUP are diagnostic tests performed on biopsy tissue. These tests can usually predict the tissue of origin, even when an anatomic primary site is not evident. If an anatomic primary site is identified, the patient no longer has CUP, and should receive site-specific treatment. These diagnostic methods include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immunohistochemistry</strong> – Improved immunohistochemistry facilitates the identification of specific cancer types, including breast, colorectal, lung, renal, and thyroid carcinomas  (<a class="graphic graphic_table graphicRef56518" href="/z/d/graphic/56518.html" rel="external">table 1</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Molecular cancer classifier assays</strong> – Molecular cancer classifier assays (MCCAs) use site-specific gene expression profiles to identify the site of origin of metastatic lesions in patients with CUP. Most studies evaluating the use of MCCA-directed site-specific therapy have been conducted in patients with adenocarcinomas of unknown primary site. (See  <a class="medical medical_review" href="/z/d/html/4877.html" rel="external">"Adenocarcinoma of unknown primary site", section on 'Molecular cancer classifier assays'</a>.)</p><p></p><p>Traditional tumor markers (carcinoembryonic antigen [CEA], cancer antigen [CA] 19-9, CA 15-3, CA 125) generally are not useful as either diagnostic or prognostic tests. These markers are often elevated in the serum of patients with adenocarcinoma of unknown primary site, and serial measurement may be useful in following the response to therapy for individual tumors. (See  <a class="medical medical_review" href="/z/d/html/2501.html" rel="external">"Clinical manifestations, diagnosis, and staging of exocrine pancreatic cancer"</a> and  <a class="medical medical_review" href="/z/d/html/767.html" rel="external">"Overview of the approach to metastatic breast cancer"</a> and  <a class="medical medical_review" href="/z/d/html/7563.html" rel="external">"Screening for ovarian cancer"</a>.)</p><p class="headingAnchor" id="H5"><span class="h2">Neuroendocrine tumors</span><span class="headingEndMark"> — </span>Neuroendocrine tumors of unknown primary site comprise approximately 1 percent of CUPs and can occur in a variety of sites  (<a class="graphic graphic_table graphicRef76723" href="/z/d/graphic/76723.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/z/d/html/4876.html" rel="external">"Neuroendocrine neoplasms of unknown primary site"</a>.)</p><p>The 2000 World Health Organization (WHO) classification system divides these tumors into low-grade and high-grade malignancies:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Low-grade neuroendocrine tumors</strong> – Metastatic carcinoid or islet cell tumors sometimes present without an obvious primary site, usually with liver metastases. In some of these patients, primary sites are subsequently identified in the intestine or pancreas.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>High-grade neuroendocrine carcinoma</strong> – Most patients with high-grade neuroendocrine carcinoma have an aggressive malignancy, usually with metastases in multiple sites [<a href="#rid11">11</a>]. Lymph nodes in the retroperitoneum and mediastinum are frequently involved.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Some patients in this group have metastatic small cell anaplastic carcinoma, which often represents a primary bronchogenic malignancy. CT of the chest and fiberoptic bronchoscopy may identify the primary site. Small cell carcinomas have also been described arising in a wide range of extrapulmonary sites, including the salivary glands, esophagus, bladder, ovary, prostate, and cervix, among others. (See  <a class="medical medical_review" href="/z/d/html/4882.html" rel="external">"Extrapulmonary small cell cancer"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Other high-grade neuroendocrine malignancies appear histologically as poorly differentiated carcinomas and are identifiable as neuroendocrine carcinomas only when immunohistochemical [IHC] stains or molecular cancer classifier assays (MCCAs) are performed. (See  <a class="medical medical_review" href="/z/d/html/4875.html" rel="external">"Poorly differentiated cancer from an unknown primary site", section on 'Molecular cancer classifier assays'</a>.)</p><p></p><p class="headingAnchor" id="H7"><span class="h2">Squamous cell carcinoma</span><span class="headingEndMark"> — </span>Squamous cell carcinoma is uncommon in the absence of an obvious primary tumor, and accounts for approximately 5 percent of CUPs. In many patients, squamous CUP is associated with human papillomavirus (HPV). (See  <a class="medical medical_review" href="/z/d/html/4880.html" rel="external">"Squamous cell carcinoma of unknown primary site"</a>.)</p><p>The clinical presentation and subsequent diagnostic evaluation of patients with squamous cell carcinoma of unknown primary site depend on the predominant area of the metastasis:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Upper and midcervical lymphadenopathy</strong> – Upper and midcervical lymphadenopathy is the most common clinical presentation of squamous CUP and is most frequently due to cancer arising in the head and neck. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lower cervical or supraclavicular lymphadenopathy</strong> – For patients with lower cervical or supraclavicular lymph nodes should be evaluated for an occult lung or head and neck primary tumor.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inguinal, pelvic, or retroperitoneal lymphadenopathy </strong>– Most patients with squamous cell carcinoma involving the inguinal, pelvic, or retroperitoneal lymph nodes should be evaluated for an anogenital primary.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adenopathy at other sites </strong>– Metastatic SCC at other sites is rare. Possible primaries include lung, skin, uterine, cervix, anal canal, or esophagus.</p><p></p><p>An MCCA may also be of value in identifying the tissue of origin in patients with squamous cell carcinoma of unknown primary site, if the evaluation described above does not identify an anatomic primary site. (See  <a class="medical medical_review" href="/z/d/html/4877.html" rel="external">"Adenocarcinoma of unknown primary site", section on 'Molecular cancer classifier assays'</a> and  <a class="medical medical_review" href="/z/d/html/4875.html" rel="external">"Poorly differentiated cancer from an unknown primary site", section on 'Molecular cancer classifier assays'</a>.)</p><p class="headingAnchor" id="H1568147757"><span class="h2">Poorly differentiated cancers</span><span class="headingEndMark"> — </span>Approximately 20 to 25 percent of all CUPs have poorly differentiated histology. Approximately 80 percent of these can be recognized as poorly differentiated carcinoma by light microscopic examination. The remainder are termed "poorly differentiated neoplasms" after initial examination, implying that the pathologist is confident of the diagnosis of malignancy but cannot distinguish between a carcinoma, sarcoma, melanoma, and hematologic malignancy based on light microscopy. (See  <a class="medical medical_review" href="/z/d/html/4875.html" rel="external">"Poorly differentiated cancer from an unknown primary site"</a>.)</p><p>Additional pathologic and molecular evaluation is essential in all poorly differentiated CUPs. The group of cancers initially termed "poorly differentiated neoplasms" contains a number of highly treatable entities, including lymphoma, germ cell tumor, and neuroendocrine carcinoma. The identity of tumors called "poorly differentiated carcinomas" by light microscopy can also be clarified. This group contains poorly differentiated neuroendocrine carcinomas and, occasionally, non-carcinomas. Additional pathologic studies are almost always successful in identifying the lineage of these tumors, and we routinely include immunohistochemistry and MCCA [<a href="#rid12">12</a>]. Electron microscopy and chromosome analysis may occasionally aid in establishing a diagnosis. (See  <a class="medical medical_review" href="/z/d/html/4875.html" rel="external">"Poorly differentiated cancer from an unknown primary site", section on 'Clinical evaluation'</a>.)</p><p>Diagnosing an occult germ cell tumor is of particular importance in this group because of the responsiveness of germ cell tumors to chemotherapy. In addition to specialized pathologic studies, elevated serum concentrations of human chorionic gonadotropin (hCG) or alpha-fetoprotein (AFP) may suggest the diagnosis of extragonadal germ cell tumor. (See  <a class="medical medical_review" href="/z/d/html/2998.html" rel="external">"Extragonadal germ cell tumors involving the mediastinum and retroperitoneum"</a>.)</p><p class="headingAnchor" id="H8"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>If an anatomic primary site is identified in a patient with CUP, the patient should no longer be considered to have CUP, and treatment should follow standard guidelines for the identified tumor type.</p><p>Several subgroups of CUP patients can be identified using the clinical and pathologic evaluation described above. Patients in the following subsets, which now comprise approximately 40 percent of all CUP patients, should receive specific therapy  (<a class="graphic graphic_table graphicRef52585" href="/z/d/graphic/52585.html" rel="external">table 3</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Females with adenocarcinoma and isolated axillary lymphadenopathy, who may benefit from treatment as for stage II breast cancer. (See  <a class="medical medical_review" href="/z/d/html/766.html" rel="external">"Axillary node metastases with occult primary breast cancer"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Females with peritoneal carcinomatosis, who may respond to treatment patterned after that used for stage III ovarian cancer. (See  <a class="medical medical_review" href="/z/d/html/4877.html" rel="external">"Adenocarcinoma of unknown primary site", section on 'Females with peritoneal carcinomatosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with clinical features and pathologic studies consistent with a colorectal primary tumor may respond well to treatment for metastatic colon cancer. This profile includes metastases involving the liver and/or peritoneum, typical histology, and immunohistochemical [IHC] staining that is cytokeratin (CK) 20 positive/CK7 negative or caudal type homeobox 2 (CDX2) positive. (See  <a class="medical medical_review" href="/z/d/html/4877.html" rel="external">"Adenocarcinoma of unknown primary site", section on 'Colon cancer profile'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with clinical features and pathologic studies consistent with non-small cell lung cancer (NSCLC) may respond to treatment for metastatic lung cancer [<a href="#rid13">13</a>]. Pathologic features for this profile can include (see  <a class="medical medical_review" href="/z/d/html/4877.html" rel="external">"Adenocarcinoma of unknown primary site", section on 'Lung adenocarcinoma profile'</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Mediastinal and/or hilar adenopathy, often accompanied by metastases at other sites</p><p class="bulletIndent2"><span class="glyph">•</span>Adenocarcinoma or squamous histology</p><p class="bulletIndent2"><span class="glyph">•</span>Typical immunohistochemistry (IHC) staining pattern (TTF-1 positive, CK7 positive, CK20 negative)</p><p class="bulletIndent2"><span class="glyph">•</span>Molecular cancer classifier assay (MCCA) prediction of NSCLC</p><p></p><p class="bulletIndent1">Management includes initial testing for programmed cell death ligand 1 (PD-L1) and critical driver mutations such as epidermal growth factor receptor (<em>EGFR</em>), the anaplastic lymphoma kinase (<em>ALK) </em>fusion oncogene, and other targetable mutations to guide selection of treatment. Further details on these molecular alterations and the treatment approach to lung cancer are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/4639.html" rel="external">"Overview of the initial treatment and prognosis of lung cancer"</a> and  <a class="medical medical_review" href="/z/d/html/4607.html" rel="external">"Overview of the initial treatment of advanced non-small cell lung cancer"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with specific pathologic findings may respond to treatment for metastatic renal cell carcinoma (RCC) [<a href="#rid13">13,14</a>]. Pathologic features for this profile can include: (See  <a class="medical medical_review" href="/z/d/html/4877.html" rel="external">"Adenocarcinoma of unknown primary site", section on 'Renal cell carcinoma profile'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Clear cell or papillary histology</p><p class="bulletIndent2"><span class="glyph">•</span>IHC staining for RCC marker, CD10, and PAX8</p><p class="bulletIndent2"><span class="glyph">•</span>MCCA diagnosis of RCC</p><p></p><p class="bulletIndent1">The management of advanced and metastatic RCC is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/15719.html" rel="external">"Overview of the treatment of renal cell carcinoma"</a> and  <a class="medical medical_review" href="/z/d/html/2984.html" rel="external">"Systemic therapy of advanced clear cell renal carcinoma"</a> and  <a class="medical medical_review" href="/z/d/html/96030.html" rel="external">"The treatment of advanced non-clear cell renal carcinoma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with clinical features and pathologic studies consistent with thyroid carcinoma may respond to treatment for metastatic follicular/papillary thyroid cancer. Pathologic features for this profile can include (see  <a class="medical medical_review" href="/z/d/html/4877.html" rel="external">"Adenocarcinoma of unknown primary site", section on 'Thyroid carcinoma profile'</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Metastases in the cervical or mediastinal lymph nodes, lungs, or bones</p><p class="bulletIndent2"><span class="glyph">•</span>Elevated serum thyroglobulin levels</p><p class="bulletIndent2"><span class="glyph">•</span>IHC staining for thyroglobulin</p><p></p><p class="bulletIndent1">The management of advanced follicular and papillary thyroid cancer is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7867.html" rel="external">"Follicular thyroid cancer (including oncocytic carcinoma of the thyroid)", section on 'Treatment'</a> and  <a class="medical medical_review" href="/z/d/html/7838.html" rel="external">"Differentiated thyroid cancer: Overview of management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Males with blastic bone metastases or an elevated serum prostate-specific antigen (PSA), in whom treatment for metastatic prostate cancer may be useful. (See  <a class="medical medical_review" href="/z/d/html/6941.html" rel="external">"Overview of systemic treatment for recurrent or metastatic castration-sensitive prostate cancer"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Squamous cell carcinoma limited to the cervical lymph nodes, which may be a manifestation of locally advanced head and neck cancer with an occult primary and should be treated as a locally advanced head and neck cancer. (See  <a class="medical medical_review" href="/z/d/html/4880.html" rel="external">"Squamous cell carcinoma of unknown primary site"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Young males with poorly differentiated mediastinal or retroperitoneal tumors, which may respond to treatment as extragonadal germ cell tumors. (See  <a class="medical medical_review" href="/z/d/html/2998.html" rel="external">"Extragonadal germ cell tumors involving the mediastinum and retroperitoneum"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Well-differentiated neuroendocrine carcinoma, for which treatment is similar to that used for advanced carcinoid tumors. (See  <a class="medical medical_review" href="/z/d/html/4876.html" rel="external">"Neuroendocrine neoplasms of unknown primary site"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Poorly differentiated neuroendocrine carcinoma, for which treatment is similar to that used for small cell lung cancer. (See  <a class="medical medical_review" href="/z/d/html/4876.html" rel="external">"Neuroendocrine neoplasms of unknown primary site"</a> and  <a class="medical medical_review" href="/z/d/html/4882.html" rel="external">"Extrapulmonary small cell cancer"</a>.)</p><p></p><p>Approximately 60 percent of patients with CUP do not fit into any of the above subgroups. For these patients, empiric chemotherapy has been considered the standard treatment. Such treatment, usually with combinations containing a platinum agent plus other cytotoxic agents (taxanes, <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">gemcitabine</a>, <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a>), has produced median survivals of 7 to 10 months and two-year survival rates of 20 to 25 percent [<a href="#rid15">15</a>]. This treatment represents an improvement when compared with historical results (median survival four to six months) [<a href="#rid16">16-18</a>]; however, the majority of patients derive only modest benefit. In addition, the improvement of therapy for many advanced solid tumors makes it increasingly unlikely that optimal therapeutic results can be achieved using a single "broad-spectrum" chemotherapy regimen. (See  <a class="medical medical_review" href="/z/d/html/4877.html" rel="external">"Adenocarcinoma of unknown primary site", section on 'Empiric chemotherapy'</a>.)</p><p>With improvements in diagnosis, particularly IHC and gene expression profiling, the tissue of origin can be accurately predicted in the majority of patients even though the anatomic primary site cannot be identified [<a href="#rid19">19</a>]. For patients who do not fit into a specific treatable subset, data are now compelling to support site-specific treatment based on prediction of the site of origin by an MCCA [<a href="#rid19">19</a>]. For patients who do not fit into a specific treatable subset, data are now compelling to support site-specific treatment based on prediction of the site of origin by an MCCA [<a href="#rid20">20-22</a>]. The benefits of this approach are most evident in patients predicted to have treatment-responsive tumor types [<a href="#rid23">23,24</a>]. (See  <a class="medical medical_review" href="/z/d/html/4877.html" rel="external">"Adenocarcinoma of unknown primary site", section on 'Molecular cancer classifier assays'</a>.)</p><p>Comprehensive molecular profiling (CMP) is an increasingly important adjunct to optimal cancer treatment. Most common cancer types have one or more identified molecular alterations for which specific targeted therapy has proven efficacious. In addition, therapies targeting several molecular abnormalities (eg, high levels of microsatellite instability [MSI-H], tumor mutational burden [TMB], <em>TRK </em>fusions) are tumor type-agnostic. Targetable molecular alterations are identified in a sizable percentage of CUP patients [<a href="#rid25">25</a>]; ongoing studies are addressing the therapeutic value of these targets. (See  <a class="medical medical_review" href="/z/d/html/4877.html" rel="external">"Adenocarcinoma of unknown primary site", section on 'Comprehensive molecular profiling'</a> and  <a class="medical medical_review" href="/z/d/html/120646.html" rel="external">"Tissue-agnostic cancer therapy: DNA mismatch repair deficiency, tumor mutational burden, and response to immune checkpoint blockade in solid tumors"</a> and  <a class="medical medical_review" href="/z/d/html/122713.html" rel="external">"TRK fusion-positive cancers and TRK inhibitor therapy"</a>.)</p><p>The treatment of patients with CUP are diagrammed in the algorithm  (<a class="graphic graphic_algorithm graphicRef86664" href="/z/d/graphic/86664.html" rel="external">algorithm 1</a>). Although not yet included in standard treatment guidelines (eg, National Comprehensive Cancer Network [NCCN] guidelines), we are convinced that site-specific therapy based on predictions by immunohistochemistry, MCCA, and CMP should be a part of the standard management of CUP patients who do not fit into a specific subset. Empiric chemotherapy should be considered for patients in whom specialized diagnostic tests are unsuccessful in predicting a primary site.</p><p class="headingAnchor" id="H9"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – Cancer of unknown primary (CUP) accounts for 1 to 2 percent of all cancer diagnoses. In many patients with CUP, the anatomic primary site is often difficult to identify despite optimal clinical and pathologic diagnostic evaluation. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial diagnostic evaluation</strong> – The initial diagnosis of advanced cancer is confirmed by biopsy of a metastatic lesion. The diagnosis of CUP is made only after specific diagnostic tests are performed and do not identify an anatomic primary site. (See <a class="local">'Initial diagnostic evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Classification of CUP</strong> – CUPs can be classified into four categories (see <a class="local">'Subsequent evaluation of CUP'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Adenocarcinoma (see  <a class="medical medical_review" href="/z/d/html/4877.html" rel="external">"Adenocarcinoma of unknown primary site"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Squamous cell carcinoma (see  <a class="medical medical_review" href="/z/d/html/4880.html" rel="external">"Squamous cell carcinoma of unknown primary site"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Neuroendocrine carcinoma, which may be either well differentiated or poorly differentiated (see  <a class="medical medical_review" href="/z/d/html/4876.html" rel="external">"Neuroendocrine neoplasms of unknown primary site"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Poorly differentiated cancer (see  <a class="medical medical_review" href="/z/d/html/4875.html" rel="external">"Poorly differentiated cancer from an unknown primary site"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – Appropriate classification can identify the approximately 40 percent of CUP patients for whom a specific treatment may be particularly useful  (<a class="graphic graphic_table graphicRef52585" href="/z/d/graphic/52585.html" rel="external">table 3</a>). For the remainder of patients, empiric chemotherapy is the standard treatment. (See <a class="local">'Treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Predicting the tissue of origin/site-specific therapy</strong> – However, accurate prediction of the tissue of origin also allows site-specific therapy in most patients. This can be achieved using techniques such as immunohistochemical [IHC] staining, molecular cancer classifier assays (MCCAs) and/or identification of targetable molecular alterations by comprehensive molecular profiling (CMP). (See  <a class="medical medical_review" href="/z/d/html/4877.html" rel="external">"Adenocarcinoma of unknown primary site", section on 'Approach to patients not included in specific subgroups'</a> and  <a class="medical medical_review" href="/z/d/html/4875.html" rel="external">"Poorly differentiated cancer from an unknown primary site", section on 'Molecular cancer classifier assays'</a>.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Rassy E, Pavlidis N. The currently declining incidence of cancer of unknown primary. Cancer Epidemiol 2019; 61:139.</a></li><li><a class="nounderline abstract_t">Karsell PR, Sheedy PF 2nd, O'Connell MJ. Computed tomography in search of cancer of unknown origin. JAMA 1982; 248:340.</a></li><li><a class="nounderline abstract_t">McMillan JH, Levine E, Stephens RH. Computed tomography in the evaluation of metastatic adenocarcinoma from an unknown primary site. A retrospective study. Radiology 1982; 143:143.</a></li><li><a class="nounderline abstract_t">Pauli C, Bochtler T, Mileshkin L, et al. A Challenging Task: Identifying Patients with Cancer of Unknown Primary (CUP) According to ESMO Guidelines: The CUPISCO Trial Experience. Oncologist 2021; 26:e769.</a></li><li><a class="nounderline abstract_t">Pentheroudakis G, Golfinopoulos V, Pavlidis N. Switching benchmarks in cancer of unknown primary: from autopsy to microarray. Eur J Cancer 2007; 43:2026.</a></li><li><a class="nounderline abstract_t">Nystrom JS, Weiner JM, Heffelfinger-Juttner J, et al. Metastatic and histologic presentations in unknown primary cancer. Semin Oncol 1977; 4:53.</a></li><li><a class="nounderline abstract_t">Rades D, Kühnel G, Wildfang I, et al. Localised disease in cancer of unknown primary (CUP): the value of positron emission tomography (PET) for individual therapeutic management. Ann Oncol 2001; 12:1605.</a></li><li><a class="nounderline abstract_t">Rusthoven KE, Koshy M, Paulino AC. The role of fluorodeoxyglucose positron emission tomography in cervical lymph node metastases from an unknown primary tumor. Cancer 2004; 101:2641.</a></li><li><a class="nounderline abstract_t">Reinert CP, Sekler J, la Fougère C, et al. Impact of PET/CT on clinical management in patients with cancer of unknown primary-a PET/CT registry study. Eur Radiol 2020; 30:1325.</a></li><li><a class="nounderline abstract_t">Møller AK, Loft A, Berthelsen AK, et al. A prospective comparison of 18F-FDG PET/CT and CT as diagnostic tools to identify the primary tumor site in patients with extracervical carcinoma of unknown primary site. Oncologist 2012; 17:1146.</a></li><li><a class="nounderline abstract_t">Hainsworth JD, Johnson DH, Greco FA. Poorly differentiated neuroendocrine carcinoma of unknown primary site. A newly recognized clinicopathologic entity. Ann Intern Med 1988; 109:364.</a></li><li><a class="nounderline abstract_t">Greco FA, Lennington WJ, Spigel DR, Hainsworth JD. Poorly differentiated neoplasms of unknown primary site: diagnostic usefulness of a molecular cancer classifier assay. Mol Diagn Ther 2015; 19:91.</a></li><li><a class="nounderline abstract_t">Rassy E, Parent P, Lefort F, et al. New rising entities in cancer of unknown primary: Is there a real therapeutic benefit? Crit Rev Oncol Hematol 2020; 147:102882.</a></li><li><a class="nounderline abstract_t">Greco FA, Hainsworth JD. Renal Cell Carcinoma Presenting as Carcinoma of Unknown Primary Site: Recognition of a Treatable Patient Subset. Clin Genitourin Cancer 2018; 16:e893.</a></li><li><a class="nounderline abstract_t">Greco FA, Pavlidis N. Treatment for patients with unknown primary carcinoma and unfavorable prognostic factors. Semin Oncol 2009; 36:65.</a></li><li><a class="nounderline abstract_t">Altman E, Cadman E. An analysis of 1539 patients with cancer of unknown primary site. Cancer 1986; 57:120.</a></li><li><a class="nounderline abstract_t">Muir C. Cancer of unknown primary site. Cancer 1995; 75:353.</a></li><li><a class="nounderline abstract_t">Riihimäki M, Hemminki A, Sundquist K, Hemminki K. Time trends in survival from cancer of unknown primary: small steps forward. Eur J Cancer 2013; 49:2403.</a></li><li><a class="nounderline abstract_t">Hainsworth JD, Greco FA. Gene expression profiling in patients with carcinoma of unknown primary site: from translational research to standard of care. Virchows Arch 2014; 464:393.</a></li><li><a class="nounderline abstract_t">Hainsworth JD, Rubin MS, Spigel DR, et al. Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research institute. J Clin Oncol 2013; 31:217.</a></li><li><a class="nounderline abstract_t">Moran S, Martínez-Cardús A, Sayols S, et al. Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis. Lancet Oncol 2016; 17:1386.</a></li><li><a class="nounderline abstract_t">Yoon HH, Foster NR, Meyers JP, et al. Gene expression profiling identifies responsive patients with cancer of unknown primary treated with carboplatin, paclitaxel, and everolimus: NCCTG N0871 (alliance). Ann Oncol 2016; 27:339.</a></li><li><a class="nounderline abstract_t">Fizazi K, Maillard A, Penel N. A phase III trial of empiric chemotherapy with cisplatin and gemcitabine or systemic treatment tailored by molecular gene expression analysis in patients with cancer of an unknown primary (CUP) site (GEFCAPI04). Ann Oncol 2019; 30:v851.</a></li><li><a class="nounderline abstract_t">Hayashi H, Kurata T, Takiguchi Y, et al. Randomized Phase II Trial Comparing Site-Specific Treatment Based on Gene Expression Profiling With Carboplatin and Paclitaxel for Patients With Cancer of Unknown Primary Site. J Clin Oncol 2019; 37:570.</a></li><li><a class="nounderline abstract_t">Ross JS, Wang K, Gay L, et al. Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site: New Routes to Targeted Therapies. JAMA Oncol 2015; 1:40.</a></li></ol></div><div id="topicVersionRevision">Topic 4878 Version 22.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31254795" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The currently declining incidence of cancer of unknown primary.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7087129" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Computed tomography in search of cancer of unknown origin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7063718" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Computed tomography in the evaluation of metastatic adenocarcinoma from an unknown primary site. A retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33687747" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : A Challenging Task: Identifying Patients with Cancer of Unknown Primary (CUP) According to ESMO Guidelines: The CUPISCO Trial Experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17698346" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Switching benchmarks in cancer of unknown primary: from autopsy to microarray.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/841350" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Metastatic and histologic presentations in unknown primary cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11822762" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Localised disease in cancer of unknown primary (CUP): the value of positron emission tomography (PET) for individual therapeutic management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15517576" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The role of fluorodeoxyglucose positron emission tomography in cervical lymph node metastases from an unknown primary tumor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31728688" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Impact of PET/CT on clinical management in patients with cancer of unknown primary-a PET/CT registry study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22711751" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : A prospective comparison of 18F-FDG PET/CT and CT as diagnostic tools to identify the primary tumor site in patients with extracervical carcinoma of unknown primary site.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2841895" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Poorly differentiated neuroendocrine carcinoma of unknown primary site. A newly recognized clinicopathologic entity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25758902" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Poorly differentiated neoplasms of unknown primary site: diagnostic usefulness of a molecular cancer classifier assay.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32106012" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : New rising entities in cancer of unknown primary: Is there a real therapeutic benefit?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29610002" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Renal Cell Carcinoma Presenting as Carcinoma of Unknown Primary Site: Recognition of a Treatable Patient Subset.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19179190" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Treatment for patients with unknown primary carcinoma and unfavorable prognostic factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3940611" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : An analysis of 1539 patients with cancer of unknown primary site.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8001006" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Cancer of unknown primary site.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23518210" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Time trends in survival from cancer of unknown primary: small steps forward.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24487792" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Gene expression profiling in patients with carcinoma of unknown primary site: from translational research to standard of care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23032625" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research institute.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27575023" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26578722" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Gene expression profiling identifies responsive patients with cancer of unknown primary treated with carboplatin, paclitaxel, and everolimus: NCCTG N0871 (alliance).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : A phase III trial of empiric chemotherapy with cisplatin and gemcitabine or systemic treatment tailored by molecular gene expression analysis in patients with cancer of an unknown primary (CUP) site (GEFCAPI04)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30653423" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Randomized Phase II Trial Comparing Site-Specific Treatment Based on Gene Expression Profiling With Carboplatin and Paclitaxel for Patients With Cancer of Unknown Primary Site.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26182302" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site: New Routes to Targeted Therapies.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
